Immuneering Corporation (Class A) (IMRX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $4.02 (+0.75% 1D, market cap $260.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMRX ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $0 in revenue, -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12% realized swing band)
FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 43.1 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IMRX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.28) and Max Pain ($4.22) forces dealer call-delta covering toward $8.90.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Immuneering Corporation (Class A) (IMRX) advanced +0.75% to $4.02, trading at 13% of its 52-week range ($3.38 – $8.48). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on e
Immuneering is developing Atebimetinib for pancreatic cancer. Early clinical data show a median overall survival of 17.3 months. I rate IMRX stock a Hold. Click to know why.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Immuneering Corporation (Class A) (IMRX) ranks #481 by composite RQD confidence (45/100, grade D) and #542 by equity capitalization ($260.1M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with IMRX at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMRX
ACTIVE
Immuneering Corporation (Class A) | D | 45/100 | — | — | -35.0% | +0.75% | $260.1M | Benchmark Subject |
| ABEO Abeona Therapeutics Inc. | D- | 39/100 | — | 73.7% | -35.0% | +0.22% | $260.8M | /abeo-vs-imrx → |
| AMRN Amarin Corporation plc | D- | 43/100 | — | 56.6% | -12.2% | -0.08% | $262.8M | /amrn-vs-imrx → |
| QTTB Q32 Bio Inc. | C- | 61/100 | 8.9x | — | 85.0% | -2.10% | $264.1M | /qttb-vs-imrx → |
| BCYC Bicycle Therapeutics plc | E | 24/100 | — | — | -35.0% | -1.55% | $267.4M | /bcyc-vs-imrx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immuneering Corporation (Class A) (IMRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$56.0M, operating cash flow of -$45.3M, and free cash flow of -$45.5M (+17.4% YoY). On the balance sheet, IMRX closed FY2025 with $232.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$56.0M | -$45.3M | -$45.5M | $232.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$61.0M | -$55.0M | -$55.1M | $52.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$53.5M | -$49.0M | -$49.0M | — | — |
As of 2026-11-01, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $4.02 (+0.75% 1D, market cap $260.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMRX ranks #481 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $0 in revenue, -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IMRX last traded at $4.02 (+0.75% on volume of 777,079 shares), positioning the stock -6.07% below its 50-day simple moving average ($4.28) and -16.42% below its 200-day simple moving average ($4.81). Across its 52-week range of $3.38 to $8.48, IMRX sits at the 12.5% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($3.54 to $4.50).
Why IMRX Stock advanced +0.75% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).